D-0825-2021 Class II Terminated
FDA drug recall D-0825-2021 was initiated by Glenmark Pharmaceuticals Inc., USA on Aug 27, 2021 and is designated Class II. Reason for recall: CGMP Deviations The recall status is terminated (terminated Oct 4, 2023). Affected quantity: 15936 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Sep 29, 2021
- Initiation Date
- Aug 27, 2021
- Termination Date
- Oct 4, 2023
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 15936 bottles
Product description
Zonisamide Capsules USP 50 mg 100 Capsules Rx Only NDC 68462-129-01 Manufactured by: Glenmark Pharmaceuticals Inc., USA Monroe, NC 28110 Manufactured for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ 07430
Reason for recall
CGMP Deviations
Distribution pattern
Nationwide.
Code information
Lots: 29190043 Exp. 05/31/2022; 29190044 Exp. 05/31/2022; 29190045 Exp. 05/31/2022
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0825-2021
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026